- Home
- PAYO vs IBRX Comparison
PAYO vs IBRX Comparison
Compare PAYO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYO | IBRX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PAYO | IBRX |
|---|---|---|
| Price | $5.88 | $2.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $9.79 | $9.71 |
| AVG Volume (30 Days) | 2.6M | ★ 11.5M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,039,820,000.00 | $82,555,000.00 |
| Revenue This Year | $11.18 | $667.18 |
| Revenue Next Year | $7.45 | $88.32 |
| P/E Ratio | $32.66 | ★ N/A |
| Revenue Growth | 10.58 | ★ 1025.95 |
| 52 Week Low | $4.92 | $1.83 |
| 52 Week High | $11.19 | $4.27 |
Technical Indicators
Market Signals| Indicator | PAYO | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 49.21 |
| Support Level | $5.61 | $2.17 |
| Resistance Level | $5.98 | $2.50 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 71.15 | 36.67 |
Price Performance
Historical ComparisonAbout PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.